Cargando…

The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch

Background: Animal model studies revealed that the application of 1-methyltryptophan (1-MT), a tryptophan (TRP) analog, surprisingly increased plasma levels of the TRP metabolite, kynurenic acid (KYNA). Under inflammatory conditions, KYNA has been shown to mediate various immunomodulatory effects. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirthgen, Elisa, Leonard, Anne K., Scharf, Christian, Domanska, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059861/
https://www.ncbi.nlm.nih.gov/pubmed/32180772
http://dx.doi.org/10.3389/fimmu.2020.00313
_version_ 1783504132349362176
author Wirthgen, Elisa
Leonard, Anne K.
Scharf, Christian
Domanska, Grazyna
author_facet Wirthgen, Elisa
Leonard, Anne K.
Scharf, Christian
Domanska, Grazyna
author_sort Wirthgen, Elisa
collection PubMed
description Background: Animal model studies revealed that the application of 1-methyltryptophan (1-MT), a tryptophan (TRP) analog, surprisingly increased plasma levels of the TRP metabolite, kynurenic acid (KYNA). Under inflammatory conditions, KYNA has been shown to mediate various immunomodulatory effects. Therefore, the present study aims to confirm and clarify the effects of 1-MT on TRP metabolism in mice as well as in humans. Methods: Splenocytes from Balb/C or indoleamine 2,3-dioxygenase knockout (IDO1(−/−)) mice or whole human blood were stimulated with 1-MT for 6, 24, or 36 h. C57BL/6 mice received 1-MT in drinking water for 5 days. Cell-free supernatants and plasma were analyzed for TRP and its metabolites by tandem mass spectrometry (MS/MS). Results: 1-MT treatment induced an increase in TRP and its metabolite, KYNA in Balb/C, IDO(−/−) mice, and in human blood. Concurrently, the intermediate metabolite kynurenine (KYN), as well as the KYN/TRP ratio, were reduced after 1-MT treatment. The effects of 1-MT on TRP metabolites were similar after the in vivo application of 1-MT to C57BL/6 mice. Conclusions: The data indicate that 1-MT induced an increase of KYNA ex vivo and in vivo confirming previously described results. Furthermore, the results of IDO(−/−) mice indicate that this effect seems not to be mediated by IDO1. Due to the proven immunomodulatory properties of KYNA, a shift toward this branch of the kynurenine pathway (KP) may be one potential mode of action by 1-MT and should be considered for further applications.
format Online
Article
Text
id pubmed-7059861
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70598612020-03-16 The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch Wirthgen, Elisa Leonard, Anne K. Scharf, Christian Domanska, Grazyna Front Immunol Immunology Background: Animal model studies revealed that the application of 1-methyltryptophan (1-MT), a tryptophan (TRP) analog, surprisingly increased plasma levels of the TRP metabolite, kynurenic acid (KYNA). Under inflammatory conditions, KYNA has been shown to mediate various immunomodulatory effects. Therefore, the present study aims to confirm and clarify the effects of 1-MT on TRP metabolism in mice as well as in humans. Methods: Splenocytes from Balb/C or indoleamine 2,3-dioxygenase knockout (IDO1(−/−)) mice or whole human blood were stimulated with 1-MT for 6, 24, or 36 h. C57BL/6 mice received 1-MT in drinking water for 5 days. Cell-free supernatants and plasma were analyzed for TRP and its metabolites by tandem mass spectrometry (MS/MS). Results: 1-MT treatment induced an increase in TRP and its metabolite, KYNA in Balb/C, IDO(−/−) mice, and in human blood. Concurrently, the intermediate metabolite kynurenine (KYN), as well as the KYN/TRP ratio, were reduced after 1-MT treatment. The effects of 1-MT on TRP metabolites were similar after the in vivo application of 1-MT to C57BL/6 mice. Conclusions: The data indicate that 1-MT induced an increase of KYNA ex vivo and in vivo confirming previously described results. Furthermore, the results of IDO(−/−) mice indicate that this effect seems not to be mediated by IDO1. Due to the proven immunomodulatory properties of KYNA, a shift toward this branch of the kynurenine pathway (KP) may be one potential mode of action by 1-MT and should be considered for further applications. Frontiers Media S.A. 2020-02-28 /pmc/articles/PMC7059861/ /pubmed/32180772 http://dx.doi.org/10.3389/fimmu.2020.00313 Text en Copyright © 2020 Wirthgen, Leonard, Scharf and Domanska. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wirthgen, Elisa
Leonard, Anne K.
Scharf, Christian
Domanska, Grazyna
The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
title The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
title_full The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
title_fullStr The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
title_full_unstemmed The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
title_short The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
title_sort immunomodulator 1-methyltryptophan drives tryptophan catabolism toward the kynurenic acid branch
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059861/
https://www.ncbi.nlm.nih.gov/pubmed/32180772
http://dx.doi.org/10.3389/fimmu.2020.00313
work_keys_str_mv AT wirthgenelisa theimmunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT leonardannek theimmunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT scharfchristian theimmunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT domanskagrazyna theimmunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT wirthgenelisa immunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT leonardannek immunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT scharfchristian immunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch
AT domanskagrazyna immunomodulator1methyltryptophandrivestryptophancatabolismtowardthekynurenicacidbranch